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Background: Influenza remains a major health problem due to the seasonal epidemics that occur every year
caused by the emergence of new influenza virus strains. Hemagglutinin (HA) and neuraminidase (NA) glycoproteins
are under selective pressure and subjected to frequent changes by antigenic drift. Therefore, our main objective
was to investigate the influenza cases in Uberlândia city, Midwestern Brazil, in order to monitor the appearance of
new viral strains, despite the availability of a prophylactic vaccine.
Methods: Nasopharyngeal samples were collected from 605 children less than five years of age presenting with
acute respiratory disease and tested by immunofluorescence assay (IFA) for detection of adenovirus, respiratory
syncytial virus, parainfluenza virus types 1, 2, and 3 and influenza virus types A and B. A reverse transcription-PCR
(RT-PCR) for influenza viruses A and B was carried out to amplify partial segments of the HA and NA genes. The
nucleotide sequences were analyzed and compared with sequences of the virus strains of the vaccine available in
the same year of sample collection.
Results: Forty samples (6.6%) were tested positive for influenza virus by IFA and RT-PCR, with 39 samples containing
virus of type A and one of type B. By RT-PCR, the type A viruses were further characterized in subtypes H3N2, H1N2
and H1N1 (41.0%, 17.9%, and 2.6%, respectively). Deduced amino acid sequence analysis of the partial hemagglutinin
sequence compared to sequences from vaccine strains, revealed that all strains found in Uberlândia had variations in
the antigenic sites. The sequences of the receptor binding sites were preserved, although substitutions with similar
amino acids were observed in few cases. The neuraminidase sequences did not show significant changes. All the H3
isolates detected in the 2001-2003 period had drifted from vaccine strain, unlike the isolates of the 2004-2007 period.
Conclusions: These results suggest that the seasonal influenza vaccine effectiveness could be reduced because of A
H3N2 variants that circulated in 2001-2003 years. Thus, an early monitoring of variants circulating in the country or in a
region may provide important information about the probable efficacy of the vaccine that will be administered in an
influenza season.
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Influenza viruses are pathogens responsible for causing
respiratory disease worldwide and represent a major
threat to public health due to annual epidemics and the
potential of pandemics. These agents are members of
Orthomyxoviridae family and are classified into types A,
B and C. Influenza viruses of type A can be further
divided into subtypes based on the antigenic properties
of the surface glycoproteins hemagglutinin (HA) and
neuraminidase (NA) [1]. Currently, 18 HA and 11 NA
variants are known [2] and they are used to subtype the
influenza virus isolates, with subtypes H1N1 and H3N2
characterized by the sustained transmission in the
human population [3]. HA and NA are under selective
pressure and undergo frequent changes through antigenic
drift, resulting in the appearance of new strains that evade
the host immune system [4]. Distinct antigenic sites
located in the H1 sequence (Sa, Sb, Ca and Cb) and five
major variable sites within domain 1 of H3 (A through E)
are targets of neutralizing antibodies and virus isolates
carrying substitutions at these sites have been related
with epidemics in humans in limited time periods
[5,6]. Vaccination is the main strategy to reduce the
public health burden caused by influenza. However, its
effectiveness depends on how close the HA sequences
of the virus strains used in the vaccine are to those
circulating in the same influenza season [7]. Sequence
analysis of the glycoprotein genes allows the identification
of new strains and may also reveal geographical regions
where the detected strains have circulated. Therefore,
knowledge of the circulating strains and genetic analysis
of HA and NA are invaluable to guide effective measures
for influenza prevention and control. In Brazil, influenza
virus sequences and strain information are currently
available from only a few locations and surveillance
efforts have been increased after the emergence of the
pandemic influenza A/H1N1 virus in humans, in 2009 [8].
In Uberlândia, in the southeastern region of the country,
however, information about circulating strains is not
known. Thus, the purposes of this study were to detect
the influenza viruses in young children presenting with
acute respiratory disease, to characterize the strains from
the identified cases and to compare the HA and NA
sequences of these strains with the sequences of the virus
variants used in the vaccines of the same flu season.
Methods
Specimens
Nasopharyngeal aspirates (NPA) were collected from
children under five years old presenting with acute
respiratory disease (ARD), within five days of onset of
clinical symptoms, as described by Costa et al. [9]. The
collection of clinical specimens was performed in public
health service units in Uberlândia city, in the state ofMinas Gerais, southeastern Brazil, from 2001 to 2010
and aliquots from the specimens were stored at −70°C.
Initially, the specimens were screened by immunofluor-
escence assay (IFA) with the Respiratory Panel I Viral
Screening and Identification Kit (Millipore/Chemicon
International, Inc., Temecula, CA, USA), following the
manufacturer’s instructions, to detect the presence of
influenza viruses A and B, respiratory syncytial viruses
A and B, parainfluenza virus types 1, 2 and 3 and
adenovirus. RT-PCR for detection of influenza virus
RNA was used with all samples that tested positive
for influenza virus by IFA and, depending on the
availability, with IFA-negative or -inconclusive samples.
The study was approved by the Ethics Committee of
Universidade Federal de Uberlândia (protocol number
326/08) and a written consent was obtained by one of
the patient’s parents.
RNA extraction and RT-PCR
Total RNA was extracted from 140 μL NPA by using
Viral RNA mini kit (Qiagen, Hilden, Germany) according
to the manufacturer’s recommendations.
For reverse transcription, the reaction was carried out
in a total volume of 20 μL, which contained 5 μL total
RNA, 0.5 mM each deoxynucleoside triphosphate, 1 μM
primer for RT (Table 1) [10], 0.1 M DTT, 100 U
SuperScript™ III Reverse Transcriptase (Life Technologies
Corp, Grand Island, NY, USA), and buffer supplied by the
enzyme manufacturer. The first three components were
mixed, incubated at 95°C for 3 min and cooled on ice for
1 min. Then, the other components were added to the
tube, the volume was completed with diethyl pyrocarbonate
(DEPC)-treated water, the mixture was incubated at 50°C
for 60 min, and the enzyme was inactivated at 95°C for
3 min. Four μL cDNA was submitted to first-round PCR, in
a total reaction volume of 20 μL, which contained 1 mM
MgCl2, 0.2 mM of each deoxyribonucleoside triphosphate, 1
or 0.25 μM each primer (for HA or NA sequence amplifica-
tion, respectively) (each sequence was amplified separately),
1 U of Platinum Taq DNA polymerase (Life Technologies)
and buffer supplied by the enzyme manufacturer. The reac-
tion was carried out with the following conditions: 94°C for
1 min; 35 cycles of 94°C for 1 min, 50°C or 55°C (respect-
ively, for HA or NA sequence amplification) for 1 min, and
72°C for 1.5 min. The first-round amplification product was
diluted 1:100 in water and 0.8 μL was submitted to a
second-round amplification, with similar conditions used in
the first-round PCR, except for the following: primer con-
centrations were changed to 0.125 or 0.25 μM (HA or NA,
respectively), MgCl2 to 1.5 mM, and annealing temperature
to 52 or 57°C (HA or NA, respectively) for 1 min. PCR
products were separated in a 1.0% agarose gel in tris-borate-
EDTA buffer [11], stained with GelRed TM (Biotium,
Hayward, CA, USA) and visualized under ultraviolet light.
Table 1 Sequences of the oligonucleotides used for cDNA synthesis, PCR amplification and sequencing reactions
Primer Sequence 5′-3′ Specificity Reaction(s) Nested-PCR amplicon
size (bp)
AH1A CAG ATG CAG ACA CAA TAT GT H1 RT, 1st-round PCR
AH1FII AAA CCG GCA ATG GCT CCA AA
AH1B ATA GGC TAC CAT GCG AAC AA 2nd-round PCR
AH1EII CTT AGT CCT GTA ACC ATC CT 944
AH3A CAG ATT GAA GTG ACT AAT GC H3 RT, 1st-round PCR
AH3DII GTT TCT CTG GTA CAT TCC GC
AH3B AGC AAA GCT TTC AGC AAC TG 2nd-round PCR
AH3CII GCT TCC ATT TGG AGT GAT GC 591
BHAA GTG ACT GGT GTG ATA CCA CT B RT, 1st-round PCR
BHADII TGT TTT CAC CCA TAT TGG GC
BHAB CAT TTT GCA AAT CTC AAA GC 2nd-round PCR
BHACII TGG AGG CAA TCT GCT TCA CC 767
AN1/418 F TTC TGA CCC AAG GTG CTC TA N1 RT, 1st- and 2nd-round PCR
AN1/EII TAC TTG TCA ATG GTG AAC GG 1st-round PCR
AN1/1219R GAA ACT TCC GCT GTA CCC TG N2 2nd-round PCR 821
AN2A/Multi AAC ATT ACT GGA TTT GCA CC RT, 1st-round PCR
AN2DII/1082 CAA AGG CCC AGC CTT TCA CT 1st- and 2nd-round PCR
AN2B GGT GAC GAG AGA ACC TTA TG 2nd-round PCR 719
H3.938.R TGT CAG AGG TTT TCA CCG TCG CTT CCA TTT GGA GTG ATG C HA1 890-909
Others
H3.101.F CAG CAC GGC AAC GCT G NA 101-116
3GSTRV TGT CAG AGG TTT TCA CCG TC
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The amplified products were purified by using GenElute
PCR Clean-Up Kit (Sigma-Aldrich, Inc., St. Louis, MO,
USA) and sequencing was performed by using either
DYEnamic™ ET Dye Terminator Kit and MegaBACE
1000 sequencer (GE Healthcare, Buckinghamshine, UK)
or BigDye Terminator v.3.1 and ABI-Prism 3100 Genetic
Analyzer (Applied Biosystems/Life Technologies, Foster
City, CA, USA), following the manufacturer’s instructions.
Sequences were edited by using SeqMan Pro (Lasergene
version 10, DNASTAR, Inc. Madison, WI, USA) and search
of similar sequences was carried out using BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Sequence alignment
was performed by using the Clustal W method in MegAlign
(DNASTAR). The nucleotide sequences of the charac-
terized isolates in this study were submitted to GenBank
under accession numbers KF918346 to KF918392.
Results
A total of 605 clinical samples were collected from
patients with ARD between 2001 and 2010 and tested by
IFA. Thirty seven (6.1%) samples showed to be reactive
for influenza viruses: 36 of type A and one of type B;
and from remaining 568 samples, 254 tested negative,122 were inconclusive, and 192 were positive for other
respiratory viruses (HRV, RSV, hMPV, PIV and Adv),
which were the subject of other studies [9,12-15].
Among the negative and inconclusive samples, 218 were
tested by RT-PCR for the amplification of HA and NA
gene segments and three other positive samples for
influenza virus type A were detected. The remaining
158 samples were not tested due to insufficient amount.
Therefore, the total prevalence found for these viruses in
the study was 6.6% (40/605).
Most children were outpatients (33/40; 82.5%),
males (26/40; 65%; p = 0.013), and the median age was
14.5 months, ranging from one to 60 months. Influenza
cases peaked in July, though they were observed from
February to September in the time period of the study.
Out of the 40 positive samples, the HA sequence
amplification by subtype-specific PCR was obtained
from 25 of them: 16 were subtyped as H3, eight as
H1, and one was characterized as type B. Regarding
NA sequence, four specimens were subtyped as N1
and 24 as N2. The subtyping of influenza A viruses
revealed that 41.0% (16/39), 17.9% (7/39) and 2.6%
(1/39) of infections were attributed to H3N2, H1N2 and
to H1N1 viruses, respectively [see Additional file 1].
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simultaneously in Uberlândia during the 2002 flu season.
Also during that year, though HA sequence from four
samples was not obtained, three viruses were identified as
subtype N1 and one as N2. Viruses with N1 subtype also
circulated in 2006 and 2009.
Comparative analysis of HA and NA sequences
For further characterization of the influenza viruses
found in Uberlândia, PCR products of HA sequence
from 25 samples and of NA sequence from 24 samples
were purified and sequenced. By using the BLAST tool,
it was observed that all Uberlandia’s strain sequences
showed high identity with sequences of influenza viruses
that had circulated previously in other regions of the
world [see Additional file 1]. Among eight HA sequences
of influenza virus subtype H1, obtained from samples
collected in 2002, six (213, 214, 215, 228, 232, and 241)
were identical to each other in the deduced amino acid
sequence and showed highest identity to an isolate that
circulated in New York in the same year.
Analysis of the HA1 domain sequence of H1 viruses
found in this study in comparison with the sequence of
the strain A/New Caledonia/20/99, which composed the
flu vaccine available from 2000 to 2007, showed that
those found in 2002 had higher nucleotide and amino
acid identities (97.9-98.5 and 97.2-98.2%, respectively) than
the one collected in 2006 (97.3 and 97.2%, respectively).
Analysis of important antigenic sites in this domain (sites
Ca, Cb, Sa and Sb) revealed a few substitutions in the
deduced amino acid sequence compared to the vaccine
strain sequence (Figure 1). All H1 viruses of this study
showed an Val to Ala substitution at position 169, which is
located within the catalytic site 1 (Ca1), and the virus














Figure 1 Alignment of the deduced amino acid sequences of domain H
sequences of 2002 H1N2 and 2006 H1N1 viruses of samples collected in Ube
Caledonia/20/99 (accession number AJ344014) that was available in the same
vaccine sequence shown at the top are represented by dots and those diverg
acid binding sites are underlined, antigenic sites Ca1, Ca2, Cb, Sa and Sb are sh
dashed open boxes. The numbering above the alignment represents the pos
sequence A/New York/399/2003 (H1N1) (accession number CY002808). * sequGly to Arg at position 240 in the same site. Moreover, the
viruses collected in 2002 had the substitution Ala to Thr at
position 193 in the Sb site.
Similarly, analyses performed with HA domain 1
sequences of influenza viruses of subtype H3 and
revealed that only three (348, 452 and 490) out of 16
nucleotide sequences were identical to sequences of
isolates that circulated in South America in the same years
of the samples collected in this study [see Additional file 1].
Three other samples (323, 333 and 412) had viruses with
their deduced amino acid sequences identical to isolates
found in the same year or in the immediately preceding
year in other countries. In comparison with sequence of
A/Moscow/10/99 H3N2 strain, which composed the
southern hemisphere (SH) vaccine distributed in the
2001–2003 period, the identities in nucleotide and
amino acid sequences varied from 94.5% and 89.0%,
respectively (sample 323), to 96.7% and 93.2%, respectively
(sample 321), both collected in 2003 (Figure 2).
Amino acid changes were observed in all antigenic sites
(A through E) in the viruses collected in the 2001–2003
period and those in antigenic sites B and E were found in
all of these viruses. Moreover, the majority of the H3 viruses
contained substitutions in three antigenic sites. Viruses
from samples 110 and 323 showed the highest number of
substitutions in the antigenic sites (11 substitutions), while
those from samples 221, 320, and 322 showed changes in
the highest number of sites (four out of five sites).
Substitutions at position 105 in sample 221 (data not
shown) and position 144 in sample 323 generated
additional N-linked glycosylation sites in the hemagglutinin
sequences (Figure 2). In the latter, the extra glycosyla-
tion site was located within the antigenic site A. A
loss of a glycosylation site was observed at position












b Sa Sb Sa SbCa2 Ca1
Ca1
A1 of subtype H1 of viral isolates found in Uberlândia. HA1 domain
rlândia were compared to the sequence of the vaccine strain A/New
period of sample collection. Residues that match the residues of the
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Figure 2 Alignment of the deduced amino acid sequences of domain HA1 of subtype H3 of viral isolates found in Uberlândia.
Sequences of H3N2 viruses of samples collected from 2001 to 2007 were compared to the strains of the vaccine available in each corresponding year:
A/Moscow/10/99 (accession number DQ487341; 2001–2003 vaccine), A/Fujian/411/2002 (accession number CY112933; 2004 vaccine), A/Wellington/1/
2004 (accession number CY012104; 2005 vaccine), A/California/7/2004 (accession number CY114373; 2006 vaccine), and A/Wisconsin/67/2005
(accession number CY114381; 2007 vaccine). Residues that match the residues of the vaccine strain sequence, which is shown at the top of each
group of sequences separated by time period, are represented by dots and those that diverge are shown, N-linked glycosylation sites are marked by
dashed boxes (including loss of a glycosylation site), residues involved in receptor binding are shaded, sialic acid binding site is underlined and the
antigenic sites A-E are shown as open boxes. The numbering above the alignment represents the positions of amino acid residues of H3 protein
according to the reference sequence A/Taiwan/30005/2004(H3N2) (accession number DQ249261).
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detected from 2004 to 2007, in comparison to the vac-
cine strain available in the respective years of the sample
collection, showed identities that varied from 96.7 to
99.1% and from 95.3 to 98.9%, respectively (Figure 2).
Regarding antigenic sites, in comparison with the se-
quence of vaccine strain available in the corresponding
year of sample collection, the majority of substitutions
of viruses detected in the six samples collected in 2004
concentrated within site B (Figure 2). Also, a substitu-
tion in the receptor binding site was observed (Leu to
His at position 183) and the virus of sample 341 con-
tained one substitution in site A; the sequence of sample
412, found in 2005, contained one substitution at site A
and another (Val to Ile) in the binding site of sialic acid; the
sequence of sample 452 of 2006 showed three substitutions
in the antigenic site B; the H3 sequence of specimen 490 of
2007 presented one substitution located in site A and
another in site E. The amino acid residue at position 226,
in the binding site of terminal sialic acid, was Ile, a substitu-
tion that was also observed with other isolates (samples
341/2004, 412/2005, and 452/2006).
In regard to neuraminidase, the nucleotide sequence
of sample 444, characterized as N1, had the highest
identity with a strain (A/Tennessee/UR06-0236/2007)
that circulated in the northern hemisphere in the same
year of the sample collection [see Additional file 1]. The
comparison with the sequence of the vaccine strain
A/New Caledonia/20/99, recommended for 2000–2007
period, showed high nucleotide and deduced amino acid
identities (98.3 and 98.0%, respectively), and the divergent
amino acid residues were at positions 187 (M, in thevaccine strain, and K in the isolate found in this study);
286(T-K); 331(E-K); 374(W-R) and 377(N-Y).
N2 nucleotide sequences from 22 H1N2 and H3N2
samples were obtained and analyzed by BLAST. Twelve
of them (213, 214, 215, 228, 232, 235, 322, 323, 330, 333,
358, and 490) had either nucleotide or deduced amino
acid sequences identical to isolates found somewhere
else in the same year or in the preceding year, and the
sequence of sample 341 was identical to the sequence of
a strain that circulated two years later in the southern
hemisphere [see Additional file 1]. The nucleotide and
deduced amino acid identities, in comparison with the
vaccine strains released from 2000–2007, varied from
97.7 and 96.9% (samples 320/321 obtained in 2003),
respectively, and 98.9% and 99.4% (sample 452 of 2006),
respectively. The conflicting amino acid residues are shown
in Table 2.
Regarding the catalytic and framework sites within the
NA sequence, the analysis showed that they were
conserved in all H1N1 and H3N2 isolates of this study
(composition of the catalytic site is R118, D151, R152,
R224, E276, R292, R371, and Y406 and composition of
the framework sites is E119, R156, W178, S179, D/N198,
I222, E227, H274, E277, N294 and E425). Nevertheless,
amino acid variations were observed in other positions
(data not shown). None of the isolates carried a known
oseltamivir resistance mutation in the NA sequence
(positions 151, 152, 222, 224, 274, 276, 292 and 294).
Discussion
Until the present study, there was no information regarding
the strains of influenza viruses circulating in Uberlândia.
Table 2 Amino acid divergent positions in neuraminidase sequences of N2 influenza isolates found in Uberlândia
between 2001 and 2007 compared with sequences of the vaccine strains of 2001–2003, 2004, 2005, 2006 and 2007
seasons
Virus strain/year Amino acid variation sites
133 141 150 160 167 172 194 199 216 221 250 254 265 267 271 285 298 307 310 332
A/Moscow/10/99a N M P K V E G K A I T P S P G V Y
110/2001 D L
* /2002 N K L
221/2002 N R K I T
241/2002 N K K L C
249.322/2003 G K I T S V
320.321/2003 G N I T N V
323/2003 V K T T S I
A/Fujian/411/2002b A T I S
330.333/2004 A I V F
341.348/2004 A T I S
339/2004 T T I S
A/Wellington/1/2004c A K I Y
412/2005 G E V W
A/California/7/2004d K
452/2006 R
A/Wisconsin/67/2005e H V L Y
490/2007 R I P H
*Samples 213, 214, 215, 228, 232, 235; aDQ487331; bCY112935; cEF512573; dCY114375; eCY114383.
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a period of ten years and the isolates were characterized
and compared with other strains.
By using immunofluorescence assay, 6.1% specimens
was tested positive for influenza viruses. A similar rate
(6.3%) was observed in a study in northeastern Brazil
[16] by using the same procedure. Still in our country,
studies carried out with children’s clinical samples, by
testing samples with IFA, cell culture isolation and/or
RT-PCR, lower rates of infection caused by influenza
viruses were reported, ranging from 1.2% - 5.0% [17-20].
On the other hand, in adults, higher rates (17.6% - 40.0%)
of respiratory disease caused by this virus have been
reported [21,22]. Still, despite lower frequencies, it is
important to emphasize the role of children in the
transmission of influenza viruses in the community,
since they shed the pathogen longer and in higher
amounts than adults [23].
Even though PCR may have higher sensitivity than IFA
[24-26], in this study not all samples that were tested
positive for influenza viruses by IFA were positive by
RT-PCR. One of the main reasons for the lower sensitivity
of RT-PCR was probably due to RNA degradation from
long-term storage [27], especially those stored at −70°C
for approximately ten years.In this study, we detected infections caused by influenza
viruses from the end of summer to the end of winter, and
this observation was consistent with the findings reported
by Carraro et al. [28] during 2001–2003 influenza seasons
in São Paulo state. Besides, the number of influenza cases
observed in the 2001–2003 period in Uberlândia was
higher than in other flu seasons, which may be the cause
of the higher rate of influenza-related morbidity reported
in other parts of the world [29].
H1N1 and H3N2 are usually the most common influenza
A subtypes found infecting humans [30], and H3N2 viruses
have been the dominant strain in most years since they first
emerged in 1968. Still, this subtype had caused one of the
most serious respiratory infections [31-33] until 2009, when
the novel swine-origin influenza H1N1 virus emerged and
was responsible for the new pandemic [34]. In this study,
H3N2 also predominated, with 41.0% of isolates that
were subtyped, and was responsible for the majority
of hospitalizations (in five out of six hospitalizations).
The co-circulation of influenza virus subtypes is found
commonly and in the 2002 season in Uberlândia, H3N2
co-circulated with subtype H1N2 and influenza B virus,
which was detected in only one clinical specimen.
Chieochansin et al. [35] also reported only one case
involving influenza B virus in 302 samples collected from
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H1N1, may have also circulated in 2002, since NA
sequences of three clinical samples were characterized
as N1. However, RNA of HA in these samples was
not detected,
In the 2000–2002 period, several H1N2 reassortant
viruses were isolated in different parts of the world
[36-38] and were also found in our study. In Brazil,
in the north region, H1N2 cases were detected between
January and April 2003 (epidemiological weeks 2 to 14)
[Personal Communications, Wyller Mello and Mirleide
Santos], whereas in Uberlândia, which is located in
the southeastern Brazil, these strains circulated as
early as July 2002.
Sequence analyses of subtypes H1N1, H1N2 and
H3N2 and influenza B virus found in this study showed
high identities with variants found in other continents
in previous years, such as in Asia, Africa and North
America, suggesting a global origin of new strains,
which are then spread to other countries through human
mobility [39,40].
Every year, WHO recommends specific vaccine strains
for influenza vaccine production. This strategy needs to
be followed since hemagglutinin and neuraminidase are
under selective pressure and undergo frequent antigenic
changes in order to evade the host’s immune system [4].
Comparison of the deduced amino acid sequences of
Uberlandia’s isolates and those of the vaccine strains
showed that they were related closely in the majority.
Precisely at antigenic site A of domain HA1, the position
144 showed higher variability, with Ile in the virus
detected in 2001, changing to Asp in 2002/2003, and to
Asn, in 2003/2004, corroborating with Bragstad et al.
[41], who reported that after 2002, this was one of the
regions in which the highest number of substitutions in
H3 subtype virus was detected. Also, divergences from
nine to 11 amino acid residues in three or four antigenic
sites, by comparing the HA sequence of the vaccine strain
and those of the viruses detected between 2001–2003,
may have caused a certain decrease in protection
efficiency of the vaccine that was available in the same time
period in Brazil – possibly configuring a mechanism of
immune evasion by these variants [42].
For H1 subtype, important amino acid changes in the
HA sequence are clustered in the variable antigenic
sites, which have been proposed based on sequence
homology to the H3 sites B + D, B, C + D + A and E,
respectively [43]. In the present study, we detected small
numbers of variations in the Ca and Sb sites in the HA
of viruses detected in 2002 and 2006 in comparison to
the vaccine strain. In H1 isolates, we found Gln and
Gly at positions 226 and 228, respectively. These
determinants, however, have been reported in H1 viruses
from both human and avian hosts [44]. In addition, H1D190 and D225 determinants of receptor-binding specifi-
city of H1N1 from humans [45] were also observed.
The antigenic regions A through E of the HA1 domain
are potential targets for neutralizing antibodies, and
amino acid changes in these regions have been associated
with annual epidemics in humans. Still, it has been
proposed that epidemiologically important drift variants
generally exhibit four or more amino acid substitutions
located in two or more antigenic sites in this domain [46].
These substitutions may generate a new strain against
which immunity acquired previously, by either infection
or vaccination, is no longer effective [47]. On the other
hand, the receptor binding sites are likely to resist changes
[48]. Our results showed that all of the 2001–2003 H3
sequences presented at least eight substitutions located at
no less than two antigenic sites. In regard to HA protein
binding to sialic acid, Leu and Ser at positions 226 and
228, respectively, have been reported to be important in
H3 subtypes and are determinants of influenza viruses
that infect humans [44]. In this study, at position 226, we
found Val in the H3N2 viruses found in the 2001–2004
period and Ile in the 2004–2007 period (Figure 2).
Nevertheless, Val and Ile, like Leu, are neutral, non-
polar amino acids and thus the presence of any of
them may have preserved the properties of the sialic
acid binding pocket of HA, as suggested by others
[49]. Still, mutations at this position may represent a
selective advantage to the virus [50].
Increasing number of N-linked glycosylation sites have
been shown to attenuate H3N2 influenza viruses in a
mouse model [51]. On the other hand, addition or removal
of a glycosylation site may generate virus variants that
evade the host immune system, including the response
generated by vaccination, and maintain a sustained circula-
tion of the virus within the human population [52]. We
found one isolate (323, Figure 2) in a sample collected in
2003 that contained an additional glycosylation site located
in an antigenic site, when compared to the vaccine strain.
Concerning the NA, variations that promote modifica-
tions in the antigenic properties usually occur in the
catalytic or framework sites of the protein [53]. The
amino acid substitutions found in the NA sequences of
the Uberlândia isolates, in comparison with the sequences
of the vaccine strains of each corresponding year, were not
located in these sites and, therefore, may not have led to
significant antigenic changes.
Circulation of naturally resistant H1N1 viruses to
oseltamivir has been reported elsewhere, even in the
absence of selective drug pressure [54]. The extensive
use of this antiviral, especially after the emergence of
the pandemic H1N1 virus, in 2009, may select and
increase the frequency of resistant variants in flu
cases. In this study, oseltamivir-resistant viruses were
not detected. It should be noted, however, that the
de Mattos Silva Oliveira et al. BMC Infectious Diseases  (2015) 15:71 Page 8 of 9sequencing was performed with RT-PCR products,
using RNA extracted from nasopharyngeal secretions.
This test does not detect the presence of low-frequency
viral variants that are resistant to this antiviral in a sample.
Conclusions
These findings constitute the first molecular epidemio-
logical study of influenza viruses in Uberlândia city,
southeastern Brazil, and are going to be used as a reference
for future studies. The genetic changes found in this inves-
tigation, mainly those characterized in important antigenic
sites, justify the continued efforts to monitor the emergence
of new viral variants in an attempt to reduce the burden
that they may cause to public health.
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